Rhythm Pharma's Imcivree generated $92.1 million in Q3; its estimated $8.25 billion market cap exceeds 20 times estimated 2026 revenue. I rate RYTM stock as Hold.
Summit Therapeutics stock sinks as regulators decline to approve ivonescimab, a next-generation cancer therapy backed by AstraZeneca.
AstraZeneca (AZN.L, AZN.ST) secured regulatory approvals in the US and the European Union for its ge
AstraZeneca (LSE:AZN) has received a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for Baxfendy (baxdrostat), a treatment for adults with hypertension that remains inadequately controlled despite taking at least two blood pressure medications. The recommendation follows results from two Phase III clinical trials demonstrating statistically significant reductions in systolic blood pressure among patients with uncontrolled or res
Compugen Ltd (CGEN) posted $3.8 million in Q3 2026 revenue, completed MAIA-ovarian enrollment with data due by Q1 2027, and holds $117.5 million in cash to fund operations into 2029.
Rhythm specializes in treatments for metabolic conditions and severe obesity.
Investing.com -- Rhythm Pharmaceuticals (NASDAQ) shares surged 28% on Wednesday after The Wall Street Journal reported that AstraZeneca (NASDAQ) had made a $10 billion acquisition offer for the biotech company.
By Sabrina Valle, Milana Vinn and Amy-Jo Crowley Nov 4 (Reuters) - AstraZeneca made an offer of about $10 billion to acquire obesity drugmaker Rhythm Pharmaceuticals, according to three people
Motley Fool Press Release.
The UK's FTSE 100 index closed the trading week 0.13% higher amid earnings releases from several cor
This is the newest page. Registered accounts read further back.